FIELD: chemistry.
SUBSTANCE: invention relates to compounds of formula (I)
or pharmaceutically acceptable salts thereof, in which: R1, R2, R3, R4, A and E are as described in the claim, and to pharmaceutical composition containing said compounds, and a method of treating and application in order to treat conditions mediated by antagonistic activity towards acid pump, such as gastrointestinal diseases, gastrooesophageal diseases, gastrooesophageal reflux disease (GERD), laryngopharyngeal reflux disease, peptic ulcers, gastric ulcers, duodenal ulcers, NSAID- induced ulcers, gastritis, Helicobacter pylori infection, dyspepsia, functional dyspepsia, Zollinger-Ellison syndrome, nonerosive reflux disease (NERD), viscerogenic pain, cancer, heartburn, nausea, oesophagitis, dysphagia, hypersalivation, disorders of the respiratory channel or asthma.
EFFECT: possibility of using compounds to treat different diseases.
9 cl, 1 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ACID PUMP ANTAGONIST FOR TREATING DISEASES ASSOCIATED WITH PATHOLOGICAL IMPAIRMENT OF GASTROINTESTINAL MOTILITY | 2010 |
|
RU2586276C2 |
| COMPOUNDS FOR THE TREATMENT OF CERTAIN LEUKOSIS | 2019 |
|
RU2804709C2 |
| COMPOUNDS AND METHODS FOR ENHANCED DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE | 2013 |
|
RU2666530C2 |
| COMPOUNDS AND METHODS FOR ENHANCING DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES, USING E3 UBIQUITIN LIGASE | 2013 |
|
RU2781452C2 |
| DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | 2014 |
|
RU2662832C2 |
| BETA-LACTAMASE INHIBITORS AND THEIR USE | 2018 |
|
RU2815314C2 |
| 1-N-PHENYLAMINO-1H-IMIDAZOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | 2004 |
|
RU2365586C2 |
| BETA-LACTAMASE INHIBITORS AND APPLICATION THEREOF | 2018 |
|
RU2753401C2 |
| PYRAZOLOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | 2015 |
|
RU2733400C2 |
| TRICYCLIC PYRROLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND USE THEREOF AS KINASE INHIBITORS | 2012 |
|
RU2591191C2 |
